drug
(cagrilintide + semaglutide)
pre_registrationupdated 3mo agoby Novo Nordisk AS
community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying (cagrilintide + semaglutide)
- phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- phase3A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- phase2A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- phase3A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
- phase2A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
- phase1A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- phase1A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
News(10)
- Novo Nordisk’s CFO on the oral Wegovy rollout and beyondNovo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss oral Wegovy’s rollout, the company’s raised outlook, why he’s still optimistic about CagriSema and more.fiercebiotech · 10d ago
- Lilly climbs, Novo falls as obesity drug battle intensifiesA research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.biopharma_dive · 11d ago
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 12d ago
- ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthNovo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…fiercebiotech · 12d ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 12d ago
- Novo dips 6% on Wegovy pill stumble despite Q2 earnings beatNovo Nordisk’s shares fell 6% on Tuesday afternoon after its second quarter earnings report showed a slight miss for the Wegovy pill vs. consensus.biospace · 12d ago
- Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.biospace · 16d ago
- Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtShareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artific…biospace · 19d ago
- Novo Nordisk fails to dismiss lawsuit over CagriSema readoutNovo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.fiercebiotech · 19d ago
- Novo hikes guidance on Wegovy pill’s fast sales startIn its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.biopharma_dive · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that